Post Reply
5021-5040 of 5072
Last chance to buy.....2nd time back to hit back day high will break throuh the roof..
dollarsense ( Date: 27-Apr-2020 13:33) Posted:
|
looks pretty cheap at this level if really this news that great
Possible to hit $0.28 today?
SmallSmall ( Date: 27-Apr-2020 13:16) Posted:
|
SmallSmall need sample ah? 🤣
SmallSmall ( Date: 27-Apr-2020 13:16) Posted:
|
Viagra with faster acting action. Imgaine the market potential. Got sample for shareholders?
IX BIOPHARMA: Stock jumps on China deal for erectile dysfunction drug
http://www.nextinsight.net/story-archive-mainmenu-60/943-2020/13488-ix-biopharma-stock-jumps-on-china-deal-for-erectile-dysfunction-drug
hope you are right!! shortist action already a bit
SmallSmall ( Date: 27-Apr-2020 10:29) Posted:
|
Small free float and great news makes a potent combination. Just need the shortists to complete the puzzle haha... Limited downside anyway.
DYODD
DYODD
SmallSmall ( Date: 27-Apr-2020 10:26) Posted:
|
Relax only first day run. News not even published by main stream broadcasters
dollarsense ( Date: 27-Apr-2020 10:24) Posted:
|
looks weak now actually
NEWS RELEASE
Licensing, supply and distribution of Wafesil& trade , sublingual sildenafil wafer, in China
Yiling Pharmaceutical Ltd. granted an exclusive licence to register and distribute Wafesil& trade , for treatment of male erectile dysfunction, in China
The agreement marks iX Biopharma& rsquo s entry into the China pharmaceutical market Singapore
Singapore, 27 April 2020 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo ) is pleased to announce that it has entered into a licensing agreement with Yiling Pharmaceutical Ltd. (&ldquo Yiling&rdquo ) for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China (the &ldquo Wafesil China Agreement&rdquo ). Under the Wafesil China Agreement, Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China. iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties.
The initial term of the agreement is 10 years. Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade . The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling. In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China. By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China.
Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million. Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® . It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe.
Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo
Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed. In addition to Wafesil&trade , iX Biopharma has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.
Licensing, supply and distribution of Wafesil& trade , sublingual sildenafil wafer, in China
Yiling Pharmaceutical Ltd. granted an exclusive licence to register and distribute Wafesil& trade , for treatment of male erectile dysfunction, in China
The agreement marks iX Biopharma& rsquo s entry into the China pharmaceutical market Singapore
Singapore, 27 April 2020 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo ) is pleased to announce that it has entered into a licensing agreement with Yiling Pharmaceutical Ltd. (&ldquo Yiling&rdquo ) for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China (the &ldquo Wafesil China Agreement&rdquo ). Under the Wafesil China Agreement, Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China. iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties.
The initial term of the agreement is 10 years. Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade . The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling. In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China. By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China.
Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million. Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® . It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe.
Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo
Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed. In addition to Wafesil&trade , iX Biopharma has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.
This one if can sell the products will be many times better than Biolidics. Men needs it every few weeks.....:)
SmallSmall ( Date: 27-Apr-2020 09:46) Posted:
|
Last chance for such cheap pricing ..... :)
SmallSmall ( Date: 27-Apr-2020 09:45) Posted:
|
This is a pretty decent company with a few very interesting patents....
Yiling estimates the first five years of sales in China for Wafesil& trade to be around RMB 700 to 800 million
SmallSmall ( Date: 27-Apr-2020 09:10) Posted:
|
Chiong ah ! Viagra play in big China market
This is going to be a ' Hard" buy. Next big medical stock play.
NEWS RELEASE Licensing, supply and distribution of Wafesil&trade , sublingual sildenafil wafer, in China Yiling Pharmaceutical Ltd. granted an exclusive licence to register and distribute Wafesil&trade , for treatment of male erectile dysfunction, in China The agreement marks iX Biopharma&rsquo s entry into the China pharmaceutical market Singapore, 27 April 2020 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo ) is pleased to announce that it has entered into a licensing agreement with Yiling Pharmaceutical Ltd. (&ldquo Yiling&rdquo ) for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China (the &ldquo Wafesil China Agreement&rdquo ). Under the Wafesil China Agreement, Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China. iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties. The initial term of the agreement is 10 years. Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade . The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling. In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China. By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China. Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million. Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® . It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe. Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed. In addition to Wafesil&trade , iX Biopharma has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.
NEWS RELEASE Licensing, supply and distribution of Wafesil&trade , sublingual sildenafil wafer, in China Yiling Pharmaceutical Ltd. granted an exclusive licence to register and distribute Wafesil&trade , for treatment of male erectile dysfunction, in China The agreement marks iX Biopharma&rsquo s entry into the China pharmaceutical market Singapore, 27 April 2020 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo ) is pleased to announce that it has entered into a licensing agreement with Yiling Pharmaceutical Ltd. (&ldquo Yiling&rdquo ) for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China (the &ldquo Wafesil China Agreement&rdquo ). Under the Wafesil China Agreement, Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China. iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties. The initial term of the agreement is 10 years. Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade . The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling. In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China. By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China. Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million. Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® . It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe. Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed. In addition to Wafesil&trade , iX Biopharma has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.
NEWS RELEASE Singapore, 10 December 2019 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo or, &ldquo the Company&rdquo ) is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublingual ketamine wafer for the treatment of acute moderate to severe pain. During the meeting, the Company and the FDA reached agreement on key aspects of the pivotal Phase 3 clinical trial program to support approval of Wafermine for the indication of acute moderate to severe pain. The Phase 3 program consists of two randomised, double blind, placebo-controlled studies, one in an orthopaedic pain model (bunionectomy) and one in a soft-tissue pain model (abdominoplasty). Both of these post-operative pain models were successfully evaluated in the recent Phase 2b clinical study. The primary efficacy measure for both studies will be SPID12, which is the summed pain intensity difference over 12 hours. The summed pain intensity difference over 24 hours (SPID24) and 48 hours (SPID48) will be evaluated as secondary endpoints. Dr. Janakan Krishnarajah, Chief Medical Officer of iX Biopharma said: " We are very pleased with the positive outcome of our meeting with the FDA and this is a major milestone for the iX Group. We appreciate the valuable guidance the FDA has provided and look forward to continuing a constructive relationship as we advance our Phase 3 registration program. We remain focused on bringing Wafermine to market as a new and differentiated nonopioid analgesic for patients and caregivers seeking alternatives to conventional opioids.&rdquo The Phase 3 studies will be using the same post-operative pain models that were successfully evaluated in the recent Phase 2b clinical study. Accordingly, the Company is highly confident that the excellent results from this study can be replicated in the final pivotal studies. More importantly, confirmation of the EOP2 meeting with the FDA gives clarity to the Wafermine development program, especially costs and timeline. Further, it positions the Company well to continue licensing discussions with potential licensees.